Utility of Whole-body Diffusion-weighted Magnetic Resonance Imaging in the Management of Treatment-related Neuroendocrine Prostate Cancer

Overview

Journal IJU Case Rep

Date 2021 Mar 15

PMID 33718807

Citations 3

Authors

Ryo Kurashina

Toshiki Kijima

Akihito Okazaki

Hirotaka Fuchizawa

Issei Suzuki

Kazumasa Sakamoto

Hironori Betsunoh

Yoshitatsu Fukabori

Masahiro Yashi

Takao Kamai

Affiliations

Soon will be listed here.

Abstract

Introduction: Treatment-related neuroendocrine prostate cancer, a rare and aggressive malignancy that emerges during androgen deprivation therapy characterized by low serum prostate-specific antigen concentrations, is challenging to monitor because it is associated with predominantly visceral and lytic bone metastases.

Case Presentation: We describe the case of a 69-year-old man with treatment-related neuroendocrine prostate cancer in whom the treatment response could be monitored using whole-body diffusion-weighted magnetic resonance imaging in addition to serum concentrations of neuroendocrine markers. The patient responded well to platinum-based chemotherapy and achieved a complete response, as evidenced by these diagnostic modalities.

Conclusion: Our case suggests that whole-body diffusion-weighted magnetic resonance imaging is useful in disease management for treatment-related neuroendocrine prostate cancer as well as the potential evaluation of mixed responses and treatment resistance.

Citing Articles

A case of double-negative prostate cancer with mutation and high tumor mutation burden treated sequentially with olaparib and pembrolizumab.

Tanaka H, Yoshida S, Aoyama S, Ikeda S, Kunieda J, Ohashi K IJU Case Rep. 2024; 7(5):395-398.

PMID: 39224671 PMC: 11366435. DOI: 10.1002/iju5.12766.

Editorial Comment to Utility of whole-body diffusion-weighted magnetic resonance imaging in the management of treatment-related neuroendocrine prostate cancer.

Yoshida S, Fujii Y IJU Case Rep. 2021; 4(2):73-74.

PMID: 33718808 PMC: 7924079. DOI: 10.1002/iju5.12248.

Utility of whole-body diffusion-weighted magnetic resonance imaging in the management of treatment-related neuroendocrine prostate cancer.

Kurashina R, Kijima T, Okazaki A, Fuchizawa H, Suzuki I, Sakamoto K IJU Case Rep. 2021; 4(2):69-73.

PMID: 33718807 PMC: 7924092. DOI: 10.1002/iju5.12242.

References

Padhani A, Lecouvet F, Tunariu N, Koh D, De Keyzer F, Collins D . Rationale for Modernising Imaging in Advanced Prostate Cancer. Eur Urol Focus. 2017; 3(2-3):223-239. DOI: 10.1016/j.euf.2016.06.018. View

Klenk C, Gawande R, Uslu L, Khurana A, Qiu D, Quon A . Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study. Lancet Oncol. 2014; 15(3):275-85. DOI: 10.1016/S1470-2045(14)70021-X. View

Xu G, Li C, Zhao L, He Z . Comparison of FDG whole-body PET/CT and gadolinium-enhanced whole-body MRI for distant malignancies in patients with malignant tumors: a meta-analysis. Ann Oncol. 2012; 24(1):96-101. DOI: 10.1093/annonc/mds234. View

Kurashina R, Kijima T, Okazaki A, Fuchizawa H, Suzuki I, Sakamoto K . Utility of whole-body diffusion-weighted magnetic resonance imaging in the management of treatment-related neuroendocrine prostate cancer. IJU Case Rep. 2021; 4(2):69-73. PMC: 7924092. DOI: 10.1002/iju5.12242. View

Spratt D, Gavane S, Tarlinton L, Fareedy S, Doran M, Zelefsky M . Utility of FDG-PET in clinical neuroendocrine prostate cancer. Prostate. 2014; 74(11):1153-9. PMC: 4355960. DOI: 10.1002/pros.22831. View

Parida G, Tripathy S, Gupta S, Singhal A, Kumar R, Bal C . Adenocarcinoma Prostate With Neuroendocrine Differentiation: Potential Utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT Over 68Ga-PSMA PET/CT. Clin Nucl Med. 2018; 43(4):248-249. DOI: 10.1097/RLU.0000000000002013. View

Beltran H, Tagawa S, Park K, MacDonald T, Milowsky M, Mosquera J . Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol. 2012; 30(36):e386-9. DOI: 10.1200/JCO.2011.41.5166. View

Palmgren J, Karavadia S, Wakefield M . Unusual and underappreciated: small cell carcinoma of the prostate. Semin Oncol. 2007; 34(1):22-9. DOI: 10.1053/j.seminoncol.2006.10.026. View

Wang H, Yao Y, Li B, Tang Y, Chang J, Zhang J . Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. J Clin Oncol. 2014; 32(30):3383-90. DOI: 10.1200/JCO.2013.54.3553. View

10.

Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N . Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol. 2004; 45(5):586-92. DOI: 10.1016/j.eururo.2003.11.032. View

11.

Wilhelm T, Stieltjes B, Schlemmer H . Whole-body-MR-diffusion weighted imaging in oncology. Rofo. 2013; 184(10):950-8. DOI: 10.1055/s-0033-1335428. View

12.

Akamatsu S, Inoue T, Ogawa O, Gleave M . Clinical and molecular features of treatment-related neuroendocrine prostate cancer. Int J Urol. 2018; 25(4):345-351. DOI: 10.1111/iju.13526. View

13.

Lecouvet F, Talbot J, Messiou C, Bourguet P, Liu Y, de Souza N . Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: a review and position statement by the European Organisation for Research and Treatment of Cancer imaging group. Eur J Cancer. 2014; 50(15):2519-31. DOI: 10.1016/j.ejca.2014.07.002. View

14.

Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M . Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med. 2004; 22(4):275-82. View

15.

Flechon A, Pouessel D, Ferlay C, Perol D, Beuzeboc P, Gravis G . Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01.... Ann Oncol. 2011; 22(11):2476-2481. DOI: 10.1093/annonc/mdr004. View

16.

Blackledge M, Collins D, Tunariu N, Orton M, Padhani A, Leach M . Assessment of treatment response by total tumor volume and global apparent diffusion coefficient using diffusion-weighted MRI in patients with metastatic bone disease: a feasibility study. PLoS One. 2014; 9(4):e91779. PMC: 3977851. DOI: 10.1371/journal.pone.0091779. View

17.

Soloway M, Hardeman S, Hickey D, Raymond J, Todd B, Soloway S . Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988; 61(1):195-202. DOI: 10.1002/1097-0142(19880101)61:1<195::aid-cncr2820610133>3.0.co;2-y. View

18.

Sterzing F, Kratochwil C, Fiedler H, Sonja Katayama , Habl G, Kopka K . (68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2015; 43(1):34-41. PMC: 4771815. DOI: 10.1007/s00259-015-3188-1. View